Olaplex Reports Q4 Revenue of $105.1M as Beauty Company Sets Sights on $435M in 2026
Olaplex posted Q4 adjusted EPS of $0.01, meeting estimates, with revenue of $105.1M and full-year 2026 guidance of $414M-$435M.
ADVERTISEMENT
Company News
Olaplex (OLPX) Meets EPS Estimates at $0.01, Guides 2026 Revenue to $414M-$435M
Olaplex posts adjusted EPS of $0.01, matching estimates, while guiding 2026 revenue to $414M-$435M as the beauty brand stabilizes.
Victoria’s Secret (VSCO) Q4 Adj. Earnings at $2.77/Share, Shares Fall 3.4%
Victoria's Secret reported a Q4 loss of $0.27/share, narrower than the $0.59 consensus, as shares fell 3.4% on the results.
Victoria’s Secret (VSCO) Reports Q4 Adj. Earnings of $2.77/Share, up 6.5%
Victoria's Secret posted a $0.27 loss per share, narrower than the $0.59 consensus, on Q4 revenue of $1.47 billion.
Myers Industries (MYE) Q4 Earnings: $0.31 EPS Beats on 230 Basis Point Margin Expansion
Myers Industries posted Q4 adjusted EPS of $0.31 with revenue of $204M, expanding operating margin 230 basis points as transformation…
Myers Industries (MYE) Q4 Adjusted EPS Surges 63% to $0.31 on Margin Expansion
Myers Industries posted Q4 adjusted EPS of $0.31, up 63% year over year, as cost savings and margin expansion offset…
Capital Clean Energy Carriers (CCEC) Posts Q4 EPS of $0.48 on $98.3M Revenue
Capital Clean Energy Carriers reports Q4 adjusted EPS of $0.48 on revenue of $98.3 million, with net income of $28.4…
Capital Clean Energy Carriers (CCEC) Reports Q4 EPS of $0.48 on $98.3M Revenue
Capital Clean Energy Carriers posts Q4 adjusted EPS of $0.48 on revenue of $98.3 million, with no consensus estimates available…
Kura Oncology Posts $0.92/Share Q4 Loss as KOMZIFTI Launch Delivers $2.1M in Initial Revenue
Kura Oncology reports wider Q4 loss of $0.92/share as KOMZIFTI launch generates $2.1M in first weeks; payers implement step edits…
Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales
Kura Oncology posted a $0.92 per share loss in Q4 2025 as KOMZIFTI generated $2.1M in debut sales, with payers…